Stockwatch: Antibodies And Coronavirus – It’s Complicated
Monoclonal Antibodies Have A Poor Antiviral Track Record
Executive Summary
The use of antibodies in disease prevention and treatment is now ingrained in modern medicine but as antiviral agents their record is at best patchy and the reliance on them to treat or prevent coronavirus infections is perhaps premature.
You may also be interested in...
Coronavirus Update: BARDA Funds AstraZeneca Antibody Research
Also: remdesivir filed in the EU.
Coronavirus Update: Lilly Begins Clinical Trial Of Antibody Therapy
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.